Bodewell Products for the Treatment of Atopic Dermatitis

NCT ID: NCT05566262

Last Updated: 2025-02-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-01
• Study Completion Date: 2027-02-28

Brief Summary

This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Bodewell Treatment

All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.

Group Type: EXPERIMENTAL

Bodewell Calming Cream

Intervention Type: DRUG

Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.

Interventions

Bodewell Calming Cream

Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. In good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co- morbid conditions).

2. 18 years of age or older

3. Able and willing to give written informed consent prior to any study procedures being conducted, and authorize the release and use of protected health information (PHI)

4. Willing to have photos taken of their skin

5. Diagnosis of chronic atopic dermatitis that has been present for at least 6 months prior to baseline

6. Atopic dermatitis involving at least 3-10 % of the patient's body surface area

7. Must have discontinued all systemic therapies for the treatment of atopic dermatitis at least 4 weeks or 5 half-lives, and biologics 6 months prior to baseline visit

8. Must have discontinued all topical therapies for the treatment of atopic dermatitis at least 2 weeks prior to baseline visit

9. Females of childbearing potential must use an approved birth control method while receiving treatment and for 28 days following the investigational product and there must be a documented negative pregnancy tests prior to initiating treatment. Approved birth control methods include hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation, partner vasectomy, or male or female condoms that are not made of natural materials PLUS a diaphragm with spermicide, cervical cap with spermicide, or a contraceptive sponge with spermicide.

Females not of child bearing potential are defined as being at least 1 year postmenopausal or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy).

10. 5 patients must be on a stable dose of systemic therapy for the last 6 months prior to screening visit

11. 5 patients must be skin of color

Exclusion Criteria

1. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled

2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study

3. Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years

4. Pregnant or breast feeding

5. Active substance abuse or a history of substance abuse within 6 months prior to Screening

6. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)

7. Prior treatment with the investigational product within 4 weeks prior to randomization

8. Unable to comply with the protocol (as defined by the Investigator; i.e. drug or alcohol abuse or history of noncompliance)

9. Any other dermatologic conditions that prohibit or confound the ability of the investigator to interpret skin findings.

10. Patients who will be unable to avoid the use of systemic steroids, excluding intranasal or inhaled steroids that will be permitted, for the duration of the trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Procter and Gamble

INDUSTRY

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Tiffany Mayo, MD

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tiffany Mayo, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

The University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ralee' B Bunt, MSPH

Role: CONTACT

erikabunt@uabmc.edu

205-502-9960

Facility Contacts

Ralee' Bunt, MSPH

Role: primary

erikabunt@uabmc.edu@uabmc.edu

205-502-9960

Other Identifiers

IRB-300008755

Identifier Type: -

Identifier Source: org_study_id